Value Microcaps Zip Code Changers

[Bobwins]

clrb +.25 to 1.83 on 3.5 million shares traded

Cellectar is a biotech with a unique approach to fighting cancer. Apparently cancer cells are water attracting so they have designed a delivery vehicle that can identify the cancer cells and deliver a drug payload to the cancer cells. This targeted delivery has been tried before in various different ways with varying degrees of success.

CLRB is in early stage trials against blood cancers. They announced today that the very first patients enrolled in their phase I trial have survived a median of 22 months. The trial has few trial participants and is early but these are very good results. These patients have multiple myeloma and have been heavily pretreated with other treatments that are no longer effective. The fact that they have survived this long with the lowest dose of CLRB's drug 131 is noteworthy.

Here is the presentation:

http://cellectar.com/wp-content/uploads/2017/06/CLRB-Corporate-Presentation-6.1.17.pdf

and today's PR

https://www.streetinsider.com/Corporate+News/Cellectar+Biosciences+%28CLRB%29+Says+CLR+131+Achieves+Overall+Survival+of+Greater+Than+22+Months+in+Advanced+Multiple+Myeloma+Patients/13179307.html